Trial record 16 of 45 for:    Dementia With Lewy Bodies

Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD))

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2013 by University Hospital, Strasbourg, France
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT01993628
First received: October 31, 2013
Last updated: November 18, 2013
Last verified: November 2013
  Purpose

Alzheimer's disease (AD) and Lewy body's dementia (LBD) are two frequent neurodegenerative pathologies. They differ in their expression, their evolution but share same features which make their diagnosis uneasy.

Constructional apraxia has been described in both disease.The underlying mechanisms have been less studied and could be different in AD and LBD.

The definition of the constructional apraxia is purely descriptive and few models are inconclusive.

It is admitted that drawing tasks involve visuo-perceptive and visuo-spatial abilities, executive functions and working memory as well as purely "constructive" skills.

Regarding to different studies, visuo-perceptive abilities are more severely impaired in LBD than in AD and are considered as an early onset sign of the disease.

Executive functions deficits are documented in AD and LDB and could contribute to the drawing impairment.

It is possible to compensate the planning disorders in giving patient the best strategy to use.

If drawing impairment persists, they should result of others mechanisms like visuo-perception, visuo-spatial or constructive deficits.

The investigators suggest that giving the best planning strategy will help more AD patients who are supposed to fail in raison of an executive impairment, than the LDB group who is supposed to present visuo-perceptive deficits. An MRI will be proposed to study the cerebral areas involved in constructional apraxia.


Condition Intervention
Alzheimer's Disease
Lewy Body's Dementia
Other: Rey figure test
Other: MRI

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Primary Outcome Measures:
  • Score obtained at the Rey figure test with a planning strategy help by LBD patients compared to the score obtained by AD patients. [ Time Frame: At inclusion ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: October 2013
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alzheimer's disease (AD)
Rey figure test and MRI
Other: Rey figure test Other: MRI
Experimental: Lewy body's dementia (LBD)
Rey figure test and MRI
Other: Rey figure test Other: MRI

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Alzheimer's disease or Lewy bodies dementia
  • ≥ 45 years
  • the cognitive impairment is mild to moderate
  • French speaker
  • a caregiver is present
  • An informed consent is signed by the patient and the p.i.

Exclusion Criteria:

  • MRI contraindication
  • Other neurological disease (FTD, brain tumor, vascular disease…)
  • Psychiatric disease (Schizophrenia, major depression, psychotic disorders, melancholia…)
  • Patient who doesn't want to be informed in case of the discovery of an abnormality
  • View or audition deficits, or motor disability which can interfere with the cognitive testing
  • Patient participating to an exclusive protocol or in the period of exclusion
  • Pregnant woman
  • Person under an administrative or legal measure of liberty privation
  • Person under a legal measure of protection or under administrative supervision
  • Person unable to give his consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01993628

Contacts
Contact: Xavier DE PETIGNY, Docteur 3 88 11 56 24 ext 0033 xavier.depetigny@chru-strasbourg.fr
Contact: PHILLIPPS Clelie, Ingenior 3 88 12 79 25 ext 0033 clelie.phillipps@chru-strasbourg.fr

Locations
France
Hôpitaux Universitaires de Strasbourg Recruiting
Strasbourg, France
Contact: Xavier De Pétigny, Docteur    3 88 12 79 25 ext 0033    xavier.depetigny@chru-strasbourg.fr   
Sponsors and Collaborators
University Hospital, Strasbourg, France
  More Information

No publications provided

Responsible Party: University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier: NCT01993628     History of Changes
Other Study ID Numbers: 5565
Study First Received: October 31, 2013
Last Updated: November 18, 2013
Health Authority: France: Ministry of Health

Additional relevant MeSH terms:
Dementia
Lewy Body Disease
Delirium, Dementia, Amnestic, Cognitive Disorders
Alzheimer Disease
Apraxias
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Mental Disorders
Psychomotor Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders

ClinicalTrials.gov processed this record on July 20, 2014